Legal changes to increase access to naloxone for opioid overdose reversal in the United States

Drug and Alcohol Dependence

Volumn 157, Issue , 2015, Pages 112-120

  Davis, Corey S ^a   Carr, Derek ^b  

^a Network for Public Health Law   (United States)

^b Network for Public Health Law   (United States)

Author keywords

Law; Naloxone; Opioids; Overdose; Public health

Indexed keywords

NALOXONE; OPIATE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ARTICLE; DRUG INTOXICATION; DRUG LEGISLATION; DRUG OVERDOSE; EMBRYO; EMERGENCY CARE; EMERGENCY HEALTH SERVICE; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; LAW ENFORCEMENT; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL SOCIETY; PATIENT SAFETY; POLITICAL PARTICIPATION; PRESCRIPTION; PRIORITY JOURNAL; RESCUE PERSONNEL; UNITED STATES; DRUG CONTROL; HEALTH CARE DELIVERY; LEGISLATION AND JURISPRUDENCE; OPIOID-RELATED DISORDERS; PHARMACY; STANDARDS; SUPPLY AND DISTRIBUTION;

ANALGESICS, OPIOID; DRUG AND NARCOTIC CONTROL; DRUG OVERDOSE; DRUG PRESCRIPTIONS; HEALTH SERVICES ACCESSIBILITY; HUMANS; NALOXONE; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; PHARMACIES; UNITED STATES;

EID: 84961391909     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2015.10.013     Document Type: Article

References (83)

1. American College of Obstetricians and Gynecologists Committee opinion no 632: expedited partner therapy in the management of gonorrhea and chlamydial infection. Obstet. Gynecol. 2015, 125:1526-1528.
2. Ashton H., Hassan Z. Best evidence topic report. Intranasal naloxone in suspected opioid overdose. Emerg. Med. J. 2006, 23:221-223.
3. Bailey A.M., Wermeling D.P. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings. Ann. Pharmacother. 2014, 48:601-606.
4. Banta-Green C.J., Beletsky L., Schoeppe J.A., Coffin P.O., Kuszler P.C. Police officers' and paramedics' experiences with overdose and their knowledge and opinions of Washington State's drug overdose-naloxone-Good Samaritan law. J. Urban Health 2013, 90:1102-1111.
5. Bardenheier B.H., Shefer A.M., Lu P.J., Remsburg R.E., Marsteller J.A. Are standing order programs associated with influenza vaccination?-NNHS, 2004. J. Am. Med. Dir. Assoc. 2010, 11:654-661.
6. Barton E.D., Ramos J., Colwell C., Benson J., Baily J., Dunn W. Intranasal administration of naloxone by paramedics. Prehosp. Emerg. Care. 2002, 6:54-58.
7. Beletsky L., Ruthazer R., Macalino G.E., Rich J.D., Tan L., Burris S. Physicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunities. J. Urban Health 2007, 84:126-136.
8. Bigg D., Maxwell S. Enabling people to stay alive: an effective opiate overdose prevention program. Fourth National Harm Reduction Conference 2002.
9. Blake V. When is a patient-physician relation established?. AMA J. Ethics 2012, 14(4):403-406.
10. Bouillon T., Bruhn J., Roepcke H., Hoeft A. Opioid-induced respiratory depression is associated with increased tidal volume variability. Eur. J. Anaesthesiol. 2003, 20:127-133.
11. Burris S., Beletsky L., Castagna C., Coyle C., Crowe C., McLaughlin J. Stopping an invisible epidemic: legal issues in the provision of naloxone to prevent opioid overdose. Drexel Law Rev. 2009, 1:273-339.
12. Burris S., Burrows D. Drug policing, harm reduction and health: directions for advocacy. Int. J. Drug Policy 2009, 20:293-295.
13. Burris S., Koester S. Investigating the intersection of policing and public health. PLoS Med. 2013, 10:e1001571.
14. Businesswire Naloxone Nasal Spray on Development Fast Track as Emergency Treatment for Opioid Overdose 2013, Businesswire.
15. Centers for Disease Control and Prevention Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR 2012, 61:101-105.
16. Chamberlain J.M., Klein B.L. A comprehensive review of naloxone for the emergency physician. Am. J. Emerg. Med. 1994, 12:650-660.
17. Chen L., Hedegaard H., Warner M. QuickStats: rates of deaths from drug poisoning and drug poisoning involving opioid analgesics-United States, 1999-2013. MMWR 2015, 64:32.
18. Chen L.H., Hedegaard H., Warner M. Drug-poisoning deaths involving opioid analgesics: United States, 1999-2011. NCHS Data Brief 2014, 1-8.
19. Clark A.K., Wilder C.M., Winstanley E.L. A systematic review of community opioid overdose prevention and naloxone distribution programs. J. Addict. Med. 2014, 8:153-163.
20. Clause S., Fudin J., Mergner A., Lutz J.L., Kavanaugh M.M., Fessler K., Chirumamilla S. Prescribing privileges among pharmacists in Veterans affairs medical centers. Am. J. Health Syst. Pharmacol. 2001, 58:1143-1145.
21. Coffin P.O., Fuller C., Vadnai L., Blaney S., Galea S., Vlahov D. Preliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City. J. Urban Health 2003, 80:288-290.
22. Coffin P.O., Sullivan S.D. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann. Intern. Med. 2013, 158:1-9.
23. Cramer R., Leichliter J.S., Stenger M.R., Loosier P.S., Slive L. The legal aspects of expedited partner therapy practice: do state laws and policies really matter?. Sex. Transm. Dis. 2013, 40:657-662. S.S.W. Group.
24. Davis C., Webb D., Burris S. Changing law from barrier to facilitator of opioid overdose prevention. J. Law Med. Ethics 2013, 41(Suppl 1):33-36.
25. Davis C.S. Legal Interventions to Reduce Overdose Mortality: Naloxone Access and Overdose Good Samaritan Laws 2015, Network for Public Health Law.
26. Davis C.S., Banta-Green C.J., Coffin P., Dailey M.W., Walley A.Y. Intranasal naloxone for opioid overdose reversal. Prehosp. Emerg. Care 2015, 19:135-137.
27. Davis C.S., Beletsky L. Bundling occupational safety with harm reduction information as a feasible method for improving police receptiveness to syringe access programs: evidence from three U.S. cities. Harm Reduct. J. 2009, 6:16.
28. Davis C.S., Carr D., Southwell J.K., Beletsky L. Engaging law enforcement in overdose reversal initiatives: authorization and liability for naloxone administration. Am. J. Public Health 2015, 105:1530-1537.
29. Davis C.S., Pierce M., Dasgupta N. Evolution and convergence of state laws governing controlled substance prescription monitoring programs, 1998-2011. Am. J. Public Health 2014, 104:1389-1395.
30. Davis C.S., Ruiz S., Glynn P., Picariello G., Walley A.Y. Expanded access to naloxone among firefighters, police officers, and emergency medical technicians in Massachusetts. Am. J. Public Health 2014, 104:e7-e9.
31. Davis C.S., Southwell J.K., Niehaus V.R., Walley A.Y., Dailey M.W. Emergency medical services naloxone access: a national systematic legal review. Acad. Emerg. Med. 2014, 21:1173-1177.
32. Davis C.S., Walley A.Y., Bridger C.M. Lessons learned from the expansion of naloxone access in Massachusetts and North Carolina. J. Law Med. Ethics 2015, 43(Suppl 1):19-22.
33. de Saxe Zerden L., O'Quinn E., Davis C. Evidence-based policy versus morality policy: the case of syringe access programs. J. Evid. Inf. Soc. Work 2015, 12:425-437.
34. Department of Health and Human Services SGM 96-2: Designation of Pharmacists as Primary Care Providers with Prescriptive Authority 1996, Department of Health and Human Services, Washington, DC.
35. Doe-Simkins M., Quinn E., Xuan Z., Sorensen-Alawad A., Hackman H., Ozonoff A., Walley A.Y. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health 2014, 14:297.
36. Doe-Simkins M., Walley A.Y., Epstein A., Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am. J. Public Health 2009, 99:788-791.
37. Enos G.A. Companies move forward in developing naloxone nasal spray formulations. Addict. Prof. 2015, http://www.addictionpro.com/news-item/companies-move-forward-developing-naloxone-nasal-spray-formulations, accessed on September 1, 2015.
38. Enteen L., Bauer J., McLean R., Wheeler E., Huriaux E., Kral A.H., Bamberger J.D. Overdose prevention and naloxone prescription for opioid users in San Francisco. J. Urban Health 2010, 87:931-941.
39. Fogel S., Singh D., Mckee C. Improving Coverage: Using State Law to Maximize Access to Family Planning and Abortion Services 2015, National Health Law Program, Washington, DC.
40. Food and Drug Administration FDA Approves New Hand-Held Auto-Injector to Reverse Opioid Overdose. First Naloxone Treatment Specifically Designed to be given by Family Members or Caregivers 2014, FDA, Washington, DC.
41. Galea S., Worthington N., Piper T.M., Nandi V.V., Curtis M., Rosenthal D.M. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence from a pilot study in New York City. Addict. Behav. 2006, 31:907-912.
42. Gliha J. The Rising Cost of Stopping Heroin Overdoses 2015, Al Jazeera America.
43. Goodman J. Naloxone, a Drug to Stop Heroin Deaths, is More Costly, the Police Say 2014, New York Times, New York, NY.
44. Green T.C., Dauria E.F., Bratberg J., Davis C.S., Walley A.Y. Orienting patients to greater opioid safety: models of community pharmacy-based naloxone. Harm Reduct. J. 2015, 12:25.
45. Haegerich T.M., Paulozzi L.J., Manns B.J., Jones C.M. What we know, and don't know, about the impact of state policy and systems-level interventions on prescription drug overdose. Drug Alcohol Depend. 2014, 145C:34-47.
46. Harvey H.H. Reducing traumatic brain injuries in youth sports: youth sports traumatic brain injury state laws January 2009-December 2012. Am. J. Public Health 2013, 103:1249-1254.
47. Hedegaard H., Chen L.H., Warner M. Drug-poisoning deaths involving heroin: United States, 2000-2013. NCHS Data Brief 2015, 1-8.
48. Hogben M., McCree D.H., Golden M.R. Patient-delivered partner therapy for sexually transmitted diseases as practiced by U.S. physicians. Sex. Transm. Dis. 2005, 32:101-105.
49. Ibrahim J.K., Anderson E.D., Burris S.C., Wagenaar A.C. State laws restricting driver use of mobile communications devices distracted-driving provisions, 1992-2010. Am. J. Prev. Med. 2011, 40:659-665.
50. Illinois Code 215 ILL. COMP. STAT. ANN. 5/356z.23 2015.
51. Internal Revenue Service IRS Notice 2010-59 2010.
52. Jones C.M. Heroin use and heroin use risk behaviors among nonmedical users of prescription opioid pain relievers-United States, 2002-2004 and 2008-2010. Drug Alcohol Depend. 2013, 132:95-100.
53. Kissinger P.J. Expedited partner therapy for sexually transmitted diseases-are we there yet?. Sex. Transm. Dis. 2014, 41:695-697.
54. Leonard-Segal A. Naloxone Expanded Access: OTC Status 2012.
55. Lewanowitsch T., Irvine R.J. Naloxone methiodide reverses opioid-induced respiratory depression and analgesia without withdrawal. Eur. J. Pharmacol. 2002, 445:61-67.
56. Lin C.J., Zimmerman R.K., Smith K.J. Cost-effectiveness of pneumococcal and influenza vaccination standing order programs. Am. J. Manage. Care 2013, 19:e30-e37.
57. Maxwell S., Bigg D., Stanczykiewicz K., Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J. Addict. Dis. 2006, 25:89-96.
58. Michiels C. Physiological and pathological responses to hypoxia. Am. J. Pathol. 2004, 164:1875-1882.
59. Middleton D.B., Lin C.J., Smith K.J., Zimmerman R.K., Nowalk M.P., Roberts M.S., Fox D.E. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients. Infect. Control Hosp. Epidemiol. 2008, 29:385-394.
60. Modarai F., Mack K., Hicks P., Benoit S., Park S., Jones C., Proescholdbell S., Ising A., Paulozzi L. Relationship of opioid prescription sales and overdoses, North Carolina. Drug Alcohol Depend. 2013, 132:81-86.
61. National Association of Boards of Pharmacy NABP Issues Policy Statement Supporting the Pharmacist's Role in Increasing Access to Opioid Overdose Reversal Drug 2014, 〈https://www.nabp.net/news/nabp-issues-policy-statement-supporting-the-pharmacist-s-role-in-increasing-access-to-opioid-overdose-reversal-drug〉 (accessed on September 12, 2015).
62. Okie S. A flood of opioids, a rising tide of deaths. N. Engl. J. Med. 2010, 363:1981-1985.
63. Pattinson K.T. Opioids and the control of respiration. Br. J. Anaesth. 2008, 100:747-758.
64. Piper T.M., Stancliff S., Rudenstine S., Sherman S., Nandi V., Clear A., Galea S. Evaluation of a naloxone distribution and administration program in New York City. Subst. Use Misuse 2008, 43:858-870.
65. Pollini R.A., Banta-Green C.J., Cuevas-Mota J., Metzner M., Teshale E., Garfein R.S. Problematic use of prescription-type opioids prior to heroin use among young heroin injectors. Subst. Abuse Rehabil. 2011, 2:173-180.
66. PR Newswire Lightlake Therapeutics Inc. Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study 2015, PR Newswire.
67. Rando J., Broering D., Olson J.E., Marco C., Evans S.B. Intranasal naloxone administration by police first responders is associated with decreased opioid overdose deaths. Am. J. Emerg. Med. 2015, 33:1201-1204.
68. Robertson T.M., Hendey G.W., Stroh G., Shalit M. Intranasal naloxone is a viable alternative to intravenous naloxone for prehospital narcotic overdose. Prehosp. Emerg. Care 2009, 13:512-515.
69. Rudd R.A., Paulozzi L.J., Bauer M.J., Burleson R.W., Carlson R.E., Dao D., Davis J.W., Dudek J., Eichler B.A., Fernandes J.C., Fondario A., Gabella B., Hume B., Huntamer T., Kariisa M., Largo T.W., Miles J., Newmyer A., Nitcheva D., Perez B.E., Proescholdbell S.K., Sabel J.C., Skiba J., Slavova S., Stone K., Tharp J.M., Wendling T., Wright D., Zehner A.M. Increases in heroin overdose deaths-28 states, 2010 to 2012. MMWR 2014, 63:849-854. Centers for Disease Control and Prevention.
70. Seal K.H., Thawley R., Gee L., Bamberger J., Kral A.H., Ciccarone D., Downing M., Edlin B.R. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J. Urban Health 2005, 82:303-311.
71. Sherman S.G., Gann D.S., Scott G., Carlberg S., Bigg D., Heimer R. A qualitative study of overdose responses among Chicago IDUs. Harm Reduct. J. 2008, 5:2.
72. Silverman B., Davis C.S., Graff J., Bhatti U., Santos M., Beletsky L. Harmonizing disease prevention and police practice in the implementation of HIV prevention programs: up-stream strategies from Wilmington Delaware. Harm Reduct. J. 2012, 9:17.
73. Simini B. Balogna-Naloxone supplied to Italian heroin addicts. Lancet 1998, 352:967.
74. Simone A. Pharmacists among Most Widely Trusted Professionals, Gallup Poll Finds 2013, Pharmacy Times.
75. Strang J., Darke S., Hall W., Farrell M., Ali R. Heroin overdose: the case for take-home naloxone. BMJ 1996, 312:1435-1436.
76. Tobin K.E., Davey M.A., Latkin C.A. Calling emergency medical services during drug overdose: an examination of individual, social and setting correlates. Addiction 2005, 100:397-404.
77. United States Code 26 USC § 106(f) 2015.
78. United States Code 42 U.S.C. 238q 2015.
79. Walley A.Y., Xuan Z., Hackman H.H., Quinn E., Doe-Simkins M., Sorensen-Alawad A., Ruiz S., Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ 2013, 346:f174.
80. Warner M., Chen L.H., Makuc D.M., Anderson R.N., Minino A.M. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011, 1-8.
81. Wheeler E., Jones T.S., Gilbert M., Davidson P. Opioid overdose prevention programs providing naloxone to laypersons. MMWR 2015, 64:631-635.
82. White J.M., Irvine R.J. Mechanisms of fatal opioid overdose. Addiction 1999, 94:961-972.
83. Yokell M.A., Green T.C., Bowman S., McKenzie M., Rich J.D. Opioid overdose prevention and naloxone distribution in Rhode Island. Med. Health R.I. 2011, 94:240-242.